3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
2
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Docetaxel
33
Prednisone
28
enzalutamide
19
Abiraterone Acetate
13
pembrolizumab
11
gallium 68 PSMA-11
9
Leuprolide
9
Radiotherapy
8
Pluvicto
8
Magnetic Resonance Spectroscopy
8
Nivolumab
7
Estramustine
7
abiraterone
6
Radiotherapy, Intensity-Modulated
6
Goserelin
6
Carboplatin
6
Biopsy
6
olaparib
5
cemiplimab
5
bicalutamide
5
Specimen Handling
5
Paclitaxel
5
Cyclophosphamide
5
temsirolimus
4
orteronel
4
darolutamide
4
cabazitaxel
4
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
4
Sirolimus
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms
×
AZD5305
×
Clear all
NCT05367440
2026-06-01
PETRANHA
AstraZeneca
Phase 1/2
Active not recruiting
174 enrolled
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled